Valuation: Mymetics Corporation

Market Cap 4L 4L 4L 3L 6L 4.23Cr 6L 42.56L 16.63L 2.08Cr 16.47L 16.12L 7.18Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.33Cr 5.89Cr 5.41Cr 10Cr 694.55Cr 10Cr 70Cr 27Cr 341.46Cr 27Cr 26Cr 1.18TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
Current year 0
Extreme 0.0003
0
1 year 0
Extreme 0.0003
0
3 years 0
Extreme 0.0003
31.01
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-100.00% 45
-0.22%+6.50%+56.82%+71.09% 5.73TCr
-1.92%+6.03%+40.64%+80.66% 5.5TCr
-0.46%-1.29%+2.86%+425.15% 2.32TCr
-2.97%-2.35%-22.53%-15.34% 2.26TCr
-1.13%+1.05%+20.81%-7.73% 2.05TCr
+0.31%+1.87%+25.64%-30.06% 1.76TCr
-0.10%+1.88%+34.42%+545.91% 1.57TCr
-1.30%-5.02%+170.77%+310.94% 1.45TCr
-0.50%-0.98%+21.43%+179.36% 1.39TCr
Average -0.83%+1.15%+35.09%+146.00% 2.4TCr
Weighted average by Cap. -1.00%+2.10%+38.44%+136.92%

Financials

2021 2022
Net sales 4L 4L 4L 3L 6L 4.14Cr 6L 41.71L 16.29L 2.04Cr 16.14L 15.79L 7.04Cr 10.28L 9L 8L 8L 14.48L 9.9Cr 14.7L 99.71L 38.96L 4.87Cr 38.59L 37.76L 17Cr
Net income -47.3L -41.54L -38.63L -35.45L -66.61L -46Cr -67.64L -4.59Cr -1.79Cr -22Cr -1.78Cr -1.74Cr -77Cr -48.05L -42.2L -39.25L -36.01L -67.67L -46Cr -68.71L -4.66Cr -1.82Cr -23Cr -1.8Cr -1.76Cr -79Cr
Net Debt 6.71Cr 5.89Cr 5.48Cr 5.03Cr 9.45Cr 646.18Cr 9.6Cr 65Cr 25Cr 317.68Cr 25Cr 25Cr 1.1TCr 7.17Cr 6.3Cr 5.86Cr 5.37Cr 10Cr 690.32Cr 10Cr 70Cr 27Cr 339.39Cr 27Cr 26Cr 1.17TCr
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock